% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Blumenfeld:303499,
author = {P. Blumenfeld and A. Pryanichnikov$^*$ and Y. Hillman and
E. Wajnryt and A. Berger and S. Winograd and M. Wygoda and
A. Salhab and M. Fang and J. Feldman and A. Popovtzer},
title = {{P}rospective clinical trial of upright image-guided proton
therapy for locally recurrent head and neck and brain
malignancies.},
journal = {Radiotherapy and oncology},
volume = {211},
issn = {0167-8140},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2025-01690},
pages = {111097},
year = {2025},
note = {#EA:E041# / Volume 211, October 2025, 111097},
abstract = {The advent of commercially available vertical CT systems
has renewed interest in gantry-less proton therapy (PT), in
which patients are treated in an upright position using a
fixed beamline and robotic positioning. This study evaluates
the feasibility, safety, and preliminary efficacy of novel
gantry-less image-guided adaptive PT (IGAPT) for recurrent
head and neck (HN) and brain malignancies.A planned interim
analysis was performed on 20 adult patients with recurrent
HN (80 $\%)$ and brain (20 $\%)$ cancers, median age 62
years, with Eastern Cooperative Oncology Group (ECOG)
performance status ≤2. Patients underwent upright and
supine imaging and simulation, followed by treatment
planning comparing upright PT to conventional supine
intensity-modulated radiotherapy (IMRT). Dosimetric analyses
focused on organ-at-risk (OAR) sparing and target coverage.
Toxicities were assessed prospectively every three months
using the Common Terminology Criteria for Adverse Events
(CTCAE).Gantry-less PT demonstrated significant dosimetric
advantages over photon IMRT, including reduced doses to
critical OARs including brainstem (6 Gy(RBE) vs. 19.1 Gy; p
< 0.001) and spinal cord (12.5 Gy(RBE) vs. 18.3 Gy; p <
0.006). At 3-month follow-up (n = 14), a complete response
was observed in 64.3 $\%$ of evaluable patients and a
partial response in 21.4 $\%.$ Most toxicities were
mild-to-moderate (grades 1-2), primarily dermatitis (55
$\%),$ fatigue (45 $\%),$ and mucositis (31.3 $\%).$ Grade 3
toxicities occurred in four patients (20 $\%).$ There were
no device-related deaths.This first clinical evaluation of a
novel gantry-less IGAPT system confirms its feasibility,
safety, and promising efficacy for recurrent HN and brain
cancer, with superior dosimetry and high local control
rates. Its cost-effective design may improve global access
to the IGAPT.},
keywords = {Adaptive radiotherapy (Other) / Image guidance (Other) /
Proton therapy (Other) / Radiotherapy (Other) / Upright CT
(Other) / Upright treatments (Other)},
cin = {E041},
ddc = {610},
cid = {I:(DE-He78)E041-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40803484},
doi = {10.1016/j.radonc.2025.111097},
url = {https://inrepo02.dkfz.de/record/303499},
}